Medexus Pharmaceuticals Inc.
MEDXF
$2.05
-$0.03-1.44%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.62M | 24.75M | 29.99M | 26.30M | 27.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.62M | 24.75M | 29.99M | 26.30M | 27.28M |
| Cost of Revenue | 8.49M | 9.96M | 13.11M | 10.66M | 11.10M |
| Gross Profit | 16.13M | 14.79M | 16.89M | 15.65M | 16.19M |
| SG&A Expenses | 12.17M | 12.17M | 10.97M | 9.69M | 10.35M |
| Depreciation & Amortization | 2.43M | 2.44M | 1.76M | 1.58M | 1.41M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.77M | 25.04M | 26.21M | 22.20M | 22.95M |
| Operating Income | 850.00K | -290.00K | 3.78M | 4.10M | 4.33M |
| Income Before Tax | 615.00K | -759.00K | 880.00K | -581.00K | 1.90M |
| Income Tax Expenses | 99.00K | -206.00K | 147.00K | -691.00K | -57.00K |
| Earnings from Continuing Operations | 516.00K | -553.00K | 733.00K | 110.00K | 1.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 516.00K | -553.00K | 733.00K | 110.00K | 1.96M |
| EBIT | 850.00K | -290.00K | 3.78M | 4.10M | 4.33M |
| EBITDA | 3.28M | 2.10M | 5.54M | 5.68M | 5.74M |
| EPS Basic | 0.02 | -0.02 | 0.03 | 0.00 | 0.08 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.02 | 0.05 | 0.06 |
| EPS Diluted | 0.02 | -0.02 | 0.03 | 0.00 | 0.08 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.02 | 0.05 | 0.06 |
| Average Basic Shares Outstanding | 32.26M | 29.60M | 24.68M | 24.55M | 24.46M |
| Average Diluted Shares Outstanding | 32.26M | 29.60M | 24.68M | 24.55M | 24.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |